MedTrace Logo

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

NCT02306291 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2019-05-17

No results posted yet for this study

Summary

This study will evaluate GMI-1271, a specific E-selectin antagonist, in acute myeloid leukemia in combination with standard agents used to treat this disease.

Conditions

  • Leukemia, Myeloid, Acute

Interventions

DRUG

GMI-1271

E-selectin antagonist

DRUG

Mitoxantrone

induction chemotherapy

DRUG

Etoposide

induction chemotherapy

DRUG

Cytarabine

induction chemotherapy

DRUG

Idarubicin

induction chemotherapy

Sponsors & Collaborators

  • GlycoMimetics Incorporated

    lead INDUSTRY

Principal Investigators

  • Daniel DeAngelo, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2017-12-31
Completion
2018-05-31

Countries

  • United States
  • Australia
  • Ireland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02306291 on ClinicalTrials.gov